FRANKFURT – Swiss drugmaker Novartis (NYSE: NVS) raised its 2024 earnings guidance for the second time on Thursday, driven by a gain in prescriptions for drugs including heart failure treatment Entresto and arthritis drug Cosentyx.
It said in a statement that full-year adjusted operating income is expected to grow by a “mid-to-high teens” percentage, where it had previously seen a “low double-digit to mid-teens” percentage.
Second-quarter adjusted operating income gained 17% to $4.95 billion, beating an average analyst estimate of just over $4.6 billion.
Sales of Entresto, Kesimpta for multiple sclerosis, and anti-inflammation drug Cosentyx, which has won approval for new uses, came in ahead of the market consensus.
The group, which has cut jobs and spun off generic-drugs business Sandoz, confirmed medium-term growth ambitions even as it is bracing for the loss of U.S. patent protection next year for its bestseller Entresto and for Promacta to treat a lack of blood platelets.
It has said it is banking on drugs like Kesimpta, which generated about $800 million in revenues last quarter, to reach $4 billion in annual sales.
Novartis (NYSE: NVS) has also billed cholesterol-lowering drug Leqvio, whose sales more than doubled to $182 million in the second quarter, as a multi-billion dollar revenue opportunity.
It reaffirmed a 5% annual currency-adjusted group sales growth target until 2028 on Thursday.
(Source: Reuters)
Zabih Ullah is a seasoned finance writer with more than ten years of experience. He is highly skilled at analyzing market trends, decoding economic data, and providing insightful commentary on various financial topics. Driven by his curiosity, Zabih stays updated with the latest developments in the finance industry, ensuring that his readers receive timely and relevant news and analysis.